ReviewIntensive care medicine2019
Challenges in severe community-acquired pneumonia: a point-of-view review.
Review in Intensive care medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06460610 (Comparative Effects of Blow Bottle and Acapella Along With Diaphragmatic Breathing in Patients With Pneumonia), which is not on this map. Cited by 98 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparative Effects of Blow Bottle and Acapella Along With Diaphragmatic Breathing in Patients With Pneumonia
Who cites it
98 citing papers in PubMed, 6 syntheses or guidelines pooled it, 189 citations in OpenAlex.
- Efficacy of traditional Chinese medicine in treating severe pneumonia: A meta-analysis and systematic review.Medicine · 2026Pooled it
- Impact of syndromic molecular diagnostics on antimicrobial adequacy and time to therapy in critically ill patients with pneumonia: a systematic review and meta-analysis of randomized trials.Critical care (London, England) · 2025Pooled it
- Risk factors for drug-resistant pathogens in community-acquired pneumonia: systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- The effect and safety of corticosteroid treatment for severe community-acquired pneumonia: a meta-analysis of randomized controlled trials.Frontiers in medicine · 2024Pooled it
- Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistantEuropean respiratory review : an official journal of the European Respiratory Society · 2023Pooled it
- Efficacy and safety of adjunctive corticosteroids in the treatment of severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials.Critical care (London, England) · 2023Pooled it
- Procalcitonin and lung ultrasound algorithm to diagnose severe pneumonia in critical paediatric patients (PROLUSP study). A randomised clinical trial.Respiratory research · 2020Trial
- Rapid diagnosis ofExperimental and therapeutic medicine · 2026Article
- Efficacy of thePakistan journal of medical sciences · 2026Article
- Article
- Predictive value of critical illness scores for outcomes of patients with community-acquired pneumonia: analysis of critical care data from the MIMIC-IV database.BMC pulmonary medicine · 2026Article
- Challenges and opportunities in the management of severe pneumonia. Key concepts from the Seventh Annual Meeting of Spanish Experts 2025.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Community-Acquired Pneumonia in Patients With Diabetes: Narrative Review.JMIR diabetes · 2026Review
- A clinically interpretable prediction model for acute mortality in patients with pneumonia requiring mechanical ventilation.Respiratory research · 2026Article
- Severe community-acquired pneumonia: an integral approach.Journal of intensive care · 2026Review
- Integrated computational and experimental evaluation of natural products targeting PGM/AlgC and HisIE in multidrug-resistant respiratory pathogens.Frontiers in microbiology · 2026Article
- Predictors of ICU Length of Stay in Patients with Severe Pneumonia: A Six-Year Retrospective Cohort Study Focusing on Traditional Chinese Medicine Adjuvant Therapy.International journal of general medicine · 2026Article
- Diagnostic efficacy of monocyte distribution width to high-sensitivity C-reactive protein ratio in differentiating pathogen types in community-acquired pneumonia: a retrospective cohort study.Open medicine (Warsaw, Poland) · 2026Article
- Appropriateness of empiric antibiotic therapy for community-acquired pneumonia: A multicenter cross-sectional study.Exploratory research in clinical and social pharmacy · 2025Article
- Clinical Features and Prediction Model of Secondary Infection Risk in Adult Patients With Chronic Respiratory Diseases: A Case-Control Study.Journal of clinical medicine research · 2025Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 8 institutions in 5 countries.
Funding
Abstract
purposeSevere community-acquired pneumonia (SCAP) is still associated with substantial morbidity and mortality. In this point-of-view review paper, a group of experts discuss the main controversies in SCAP: the role of severity scores to guide patient settings of care and empiric antibiotic therapy; the emergence of pathogens outside the core microorganisms of CAP; viral SCAP; the best empirical treatment; septic shock as the most lethal complication; and the need for new antibiotics.
methodsFor all topics, the authors describe current controversies and evidence and provide recommendations and suggestions for future research. Evidence was based on meta-analyses, most recent RCTs and recent interventional or observational studies. Recommendations were reached by consensus of all the authors. RESULTS AND
conclusionsThe IDSA/ATS criteria remain the most pragmatic tool to predict ICU admission. The authors recommend a combination of a beta-lactam/beta-lactamase inhibitor or a third G cephalosporin plus a macrolide in most SCAP patients, and to empirically cover PES (P. aeruginosa, extended spectrum beta-lactamase producing Enterobacteriaceae, methicillin-resistant S. aureus) pathogens when at least two specific risk factors are present. In patients with influenza CAP, the authors recommend the use of oseltamivir and avoidance of the use of steroids. Corticosteroids can be used in case of refractory shock and high systemic inflammatory response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.